<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625724</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0337</org_study_id>
    <nct_id>NCT05625724</nct_id>
  </id_info>
  <brief_title>Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology</brief_title>
  <acronym>APPART</acronym>
  <official_title>Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women After Assisted Reproductive Technology. APPART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted&#xD;
      Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications&#xD;
      and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in&#xD;
      the prevention of preterm preeclampsia and other perinatal adverse outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia (PE) affects 2% of pregnancies in France and is an important cause of maternal&#xD;
      and perinatal mortality and morbidity. Aspirin is currently the only prophylactic therapy for&#xD;
      PE in high-risk women when initiated before 16 weeks of gestation and at a daily dose of&#xD;
      100-160 mg, with a reduction in the incidence of preterm preeclampsia of 60-70% in recent&#xD;
      meta-analysis. Latest data also demonstrate a potential beneficial effect of aspirin on&#xD;
      spontaneous preterm birth. A major challenge in modern obstetrics is early identification of&#xD;
      pregnant women at high-risk of PE who could benefit from aspirin treatment. In France, the&#xD;
      College National des Gynécologues et Obstétriciens Français and the Société Française&#xD;
      d'HyperTension Artérielle have restrictive recommendation of aspirin to be prescribed only to&#xD;
      women with a history of PE or vascular intra-uterine growth restriction, thus leaving out all&#xD;
      nulliparous women (including those with multiple risk factors). Other countries (USA, UK,&#xD;
      Canada) have much broader recommendations with aspirin prescription for patients with one&#xD;
      high or 2 moderate risk factors, but exposing nearly 30% of pregnant women to aspirin&#xD;
      (leading to unnecessary exposure to treatment). The Fetal Medicine Foundation provides a&#xD;
      screening test combining clinical parameters, uterine artery Doppler, and biomarkers; but&#xD;
      this strategy has high false-positive rate and the reproducibility needs to be confirmed in&#xD;
      clinical practice.&#xD;
&#xD;
      It seems necessary to be able to better target women at risk, especially in nulliparous&#xD;
      women. Nulliparity and assisted reproductive technology (ART) are independent risk factors&#xD;
      for PE. Currently the proportion of pregnancy after ART in France is roughly 6.9% and is&#xD;
      rising. Nulliparous ART pregnant women have a higher risk of PE and preterm birth. Indeed,&#xD;
      they commonly cumulate risk factors including age&gt;35years in association with nulliparity and&#xD;
      ART. The rate of PE in this population can rise up to 10%.&#xD;
&#xD;
      Our hypothesis is that nulliparous pregnant women after ART are at high risk of preeclampsia&#xD;
      and perinatal complications and represent a subgroup for which aspirin prophylaxis during&#xD;
      pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal&#xD;
      adverse outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2023</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo in the prevention of preterm (&lt;37 weeks of gestation) preeclampsia</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of preterm (&lt;37 weeks of gestation) preeclampsia (binary variable yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on spontaneous and total preterm birth &lt;34 weeks of gestation</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Occurrence of spontaneous and total preterm birth (defined by delivery at &lt;34 weeks of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on spontaneous and total preterm birth &lt;37 weeks of gestation</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of spontaneous and total preterm birth (defined by delivery at &lt;37weeks of gestation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on occurrence of preeclampsia &lt;34 weeks of gestation, term preeclampsia (≥ 37 weeks of gestation)</measure>
    <time_frame>Up to 8 months</time_frame>
    <description>Occurrence of term (≥37 weeks) preeclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on occurrence of cesarean delivery</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on occurrence of postpartum hemorrhage (&gt;500ml)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of postpartum hemorrhage (&gt;500ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on occurrence of placental abruption</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of placental abruption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of aspirin 150mg daily initiated between 9 and 14 weeks of gestation versus placebo on neonatal adverse outcome.</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Occurrence of neonatal adverse outcomes: still birth, neonatal death, neonatal complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1164</enrollment>
  <condition>ART</condition>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose Aspirin: 150mg, daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo administrated daily, oral route, at bedtime, initiated between 9 and 14 weeks of gestation, until 35 (+6) weeks of gestation, or in the event of earlier delivery, until the onset of labor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Experimental drug administrated orally</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment for the control group</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Nulliparous women aged 18 years or more&#xD;
&#xD;
          -  Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic&#xD;
             sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Evolutive pregnancy between 9 and 14 weeks of gestation&#xD;
&#xD;
          -  Women affiliated to a French Social Security Insurance or equivalent social protection&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major fetal abnormality&#xD;
&#xD;
          -  Regular treatment with aspirin (including antiphospholipid syndrome)&#xD;
&#xD;
          -  Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration,&#xD;
             hemophilia)&#xD;
&#xD;
          -  Women protected by law.&#xD;
&#xD;
          -  Women included in another interventional study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe VAYSSIERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>vayssiere.c@chu-toulouse.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul GUERBY, MD</last_name>
    <phone>5 67 77 12 33</phone>
    <email>guerby.p@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine DUCHANOIS, Midwife</last_name>
    <phone>5 67 77 12 33</phone>
    <phone_ext>+33</phone_ext>
    <email>duchanois.d@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Emmanuel BOUET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel BOUET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loic Sentilhes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Loic SENTILHES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amélie DELABAERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amélie DELABAERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel Simon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel SIMON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Véronique Debarge, MD</last_name>
    </contact>
    <investigator>
      <last_name>Véronique DEBARGE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Groupement Hospitalier Est, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mona Massoud, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mona MASSOUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Blandine Courbière, MD</last_name>
    </contact>
    <investigator>
      <last_name>Blandine COURBIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie Blanc, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julie BLANC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Noémie Ranisavljevic, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noémie RANISAVLJEVIC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Zuili Lamy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine ZUILI LAMY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent Dochez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent DOCHEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphanie Huberlant, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphanie HUBERLANT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier St Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elie Azria, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elie AZRIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand - Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles Kayem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles KAYEM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vassilis Tsatsaris, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vassilis TSATSARIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Poissy Saint Germain en Laye</name>
      <address>
        <city>Poissy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Berveiller, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul BERVEILLER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aurélie Brossard Violeau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélie BROSSARD VIOLEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne, Hôpital Nord</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiphaine Barjat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tiphaine BARJAT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine Rongières, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine RONGIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul GUERBY, MD</last_name>
      <email>guerby.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe VAYSSIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck Perrotin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franck PERROTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>November 22, 2022</last_update_submitted>
  <last_update_submitted_qc>November 22, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

